Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine in Adults and Elderly
NCT00841646Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2008
- Primary completion
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated), sponsored by Novartis. Started Dec 2008; status: completed.
02
Drugs
Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
Beyond the preview
Go deeper on NCT00841646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841646.